What is Merck & Co.'s derivative liabilities - fair value?

Merck & Co. (MRK) reported derivative liabilities - fair value of $225M in Q1 2026.

How has Merck & Co.'s derivative liabilities - fair value changed year-over-year?

Merck & Co.'s derivative liabilities - fair value decreased by 5.9% year-over-year, from $239M to $225M.

What is the long-term trend for Merck & Co.'s derivative liabilities - fair value?

Over 5 years (2020 to 2025), Merck & Co.'s derivative liabilities - fair value has grown at a 9.4% compound annual growth rate (CAGR), from $156M to $245M.

Merck & Co. MRK Derivative Liabilities - Fair Value

Derivative Liabilities - Fair Value at other companies

CytokineticsCYTK

$29.6M+153%

Spyre Therapeutics, Inc.SYRE

$50.26M+17.4%

PfizerPFE

——

ImmunityBio, Inc.IBRX

——

AbbVieABBV

——

AmgenAMGN

——

Other financials

Income statement

See full

Revenue$16.3B+4.9%

Gross profit$12.1B-0.2%

Net income-$4.2B-183%

EPS (diluted)-$1.72-186%

Balance sheet

See full

Cash & equivalents$5.4B-38.2%

Total debt$49.1B+35.8%

Total equity$45.9B-5.1%

Total assets$128.69B+11.8%

Cash flow

See full

Operating cash flow$3.9B+56.7%

CapEx$991.0M-25.4%

Free cash flow$2.9B+150%

Valuation

See full

Market cap$281.24B+31.2%

Enterprise value$324.94B+34.2%

P/E31.5×+19.2×

P/S4.3×+0.9×

Profitability

See full

Gross margin73.9%-2.5pp

Net margin13.6%-13.7pp

FCF margin21.5%-5.2pp

Returns & leverage

See full

Return on equity19%-20.3pp

Debt / equity1.1×+0.3×

Current ratio1.3×-0.1×

Where this comes from

Reported directly by Merck & Co. in its filing.

Tagged under the XBRL concept us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction.

The official record: Merck & Co.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Merck & Co.'s derivative liabilities - fair value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Merck & Co.'s derivative liabilities - fair value?: Merck & Co. (MRK) reported derivative liabilities - fair value of $225M in Q1 2026.
How has Merck & Co.'s derivative liabilities - fair value changed year-over-year?: Merck & Co.'s derivative liabilities - fair value decreased by 5.9% year-over-year, from $239M to $225M.
What is the long-term trend for Merck & Co.'s derivative liabilities - fair value?: Over 5 years (2020 to 2025), Merck & Co.'s derivative liabilities - fair value has grown at a 9.4% compound annual growth rate (CAGR), from $156M to $245M.